Skip to main content
Erschienen in: Herz 4/2022

14.06.2022 | Akutes Koronarsyndrom | CME

Management des akuten Koronarsyndroms ohne ST-Strecken-Hebung

verfasst von: PD Dr. Maria Rubini Gimenez, Prof. Dr. Holger Thiele, PD Dr. med. Janine Pöss

Erschienen in: Herz | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Sammelbegriff „akutes Koronarsyndrom“ (ACS) umfasst den ST-Strecken-Hebungs-Infarkt (STEMI) und das ACS ohne ST-Strecken-Hebung (NSTE-ACS). Letzteres umfasst den akuten Myokardinfarkt ohne ST-Strecken-Hebung (NSTEMI) und die instabile Angina pectoris. Nach der Diagnosestellung eines STEMI ist eine sofortige Zuweisung in das Herzkatheterlabor erforderlich; Diagnostik und Management des NSTE-ACS sind anspruchsvoller. Die aktuellen Leitlinien der European Society of Cardiology (ESC) zur Behandlung des NSTE-ACS wurden 2020 publiziert. Dabei werden die Themen Diagnostik, Risikostratifizierung, antithrombotische Therapie, invasive oder nicht-invasive Koronardiagnostik sowie die Langzeittherapie behandelt. Der Schwerpunkt der Leitlinie liegt auf der Verwendung hoch sensitiver kardialer Troponinassays (hs-cTn) in Verbindung mit verifizierten Diagnosealgorithmen, um eine zügige Triage-Entscheidung („rule-out“ = sicher kein NSTEMI oder „rule-in“ = NSTEMI wahrscheinlich) in der Notaufnahme oder der Chest Pain Unit zu ermöglichen.
Literatur
1.
Zurück zum Zitat Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 37:267–315CrossRef Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 37:267–315CrossRef
3.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS et al (2018) Fourth universal definition of myocardial infarction. Eur Heart J 40:237–269CrossRef Thygesen K, Alpert JS, Jaffe AS et al (2018) Fourth universal definition of myocardial infarction. Eur Heart J 40:237–269CrossRef
5.
Zurück zum Zitat Ibanez B, James S, Agewall S et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed) 70:1082CrossRef Ibanez B, James S, Agewall S et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed) 70:1082CrossRef
6.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS et al (2018) Fourth universal definition of myocardial infarction. Circulation 138:e618–e651CrossRef Thygesen K, Alpert JS, Jaffe AS et al (2018) Fourth universal definition of myocardial infarction. Circulation 138:e618–e651CrossRef
7.
Zurück zum Zitat Chew DP, Lambrakis K, Blyth A et al (2019) A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the rapid assessment of possible acute coronary syndrome in the emergency department with high-sensitivity troponin T study (RAPID-TnT). Circulation 140:1543–1556CrossRef Chew DP, Lambrakis K, Blyth A et al (2019) A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the rapid assessment of possible acute coronary syndrome in the emergency department with high-sensitivity troponin T study (RAPID-TnT). Circulation 140:1543–1556CrossRef
8.
Zurück zum Zitat Stoyanov KM, Hund H, Biener M et al (2020) RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. Eur Heart J Acute Cardiovasc Care 9:39–51CrossRef Stoyanov KM, Hund H, Biener M et al (2020) RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. Eur Heart J Acute Cardiovasc Care 9:39–51CrossRef
9.
Zurück zum Zitat Twerenbold R, Costabel JP, Nestelberger T et al (2019) Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocardial infarction. J Am Coll Cardiol 74:483–494CrossRef Twerenbold R, Costabel JP, Nestelberger T et al (2019) Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocardial infarction. J Am Coll Cardiol 74:483–494CrossRef
10.
Zurück zum Zitat Reichlin T, Hochholzer W, Stelzig C et al (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60–68CrossRef Reichlin T, Hochholzer W, Stelzig C et al (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60–68CrossRef
11.
Zurück zum Zitat Mockel M, Searle J, Hamm C et al (2015) Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 36:369–376CrossRef Mockel M, Searle J, Hamm C et al (2015) Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 36:369–376CrossRef
12.
Zurück zum Zitat Keller T, Tzikas S, Zeller T et al (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106CrossRef Keller T, Tzikas S, Zeller T et al (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106CrossRef
13.
Zurück zum Zitat Wildi K, Boeddinghaus J, Nestelberger T et al (2019) Comparison of fourteen rule-out strategies for acute myocardial infarction. Int J Cardiol 283:41–47CrossRef Wildi K, Boeddinghaus J, Nestelberger T et al (2019) Comparison of fourteen rule-out strategies for acute myocardial infarction. Int J Cardiol 283:41–47CrossRef
14.
Zurück zum Zitat Vargas KG, Kassem M, Mueller C et al (2016) Copeptin for the early rule-out of non-ST-elevation myocardial infarction. Int J Cardiol 223:797–804CrossRef Vargas KG, Kassem M, Mueller C et al (2016) Copeptin for the early rule-out of non-ST-elevation myocardial infarction. Int J Cardiol 223:797–804CrossRef
15.
Zurück zum Zitat Mueller C, Mockel M, Giannitsis E et al (2018) Use of copeptin for rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 7:570–576CrossRef Mueller C, Mockel M, Giannitsis E et al (2018) Use of copeptin for rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 7:570–576CrossRef
16.
Zurück zum Zitat Restan IZ, Sanchez AY, Steiro OT et al (2022) Adding stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation myocardial infarction rule-out protocols. Eur Heart J Acute Cardiovasc Care 11:201–212CrossRef Restan IZ, Sanchez AY, Steiro OT et al (2022) Adding stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation myocardial infarction rule-out protocols. Eur Heart J Acute Cardiovasc Care 11:201–212CrossRef
17.
Zurück zum Zitat Chew DP, Astley CM, Luker H et al (2015) A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: rationale and design of the Australian GRACE risk score intervention study (AGRIS). Am Heart J 170:995–1004.e1CrossRef Chew DP, Astley CM, Luker H et al (2015) A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: rationale and design of the Australian GRACE risk score intervention study (AGRIS). Am Heart J 170:995–1004.e1CrossRef
18.
Zurück zum Zitat Zeymer U, Schneider S, Zahn R, Andresen D (2014) Reported underuse of risk scores in patients with acute coronary syndromes without persistent ST elevations in clinical practice: results of a survey of the ALKK study group. Clin Res Cardiol 103:83–84CrossRef Zeymer U, Schneider S, Zahn R, Andresen D (2014) Reported underuse of risk scores in patients with acute coronary syndromes without persistent ST elevations in clinical practice: results of a survey of the ALKK study group. Clin Res Cardiol 103:83–84CrossRef
19.
Zurück zum Zitat Urban P, Mehran R, Colleran R et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J 40:2632–2653CrossRef Urban P, Mehran R, Colleran R et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J 40:2632–2653CrossRef
20.
Zurück zum Zitat Ueki Y, Bar S, Losdat S et al (2020) Validation of the academic research consortium for high bleeding risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention 16:371–379CrossRef Ueki Y, Bar S, Losdat S et al (2020) Validation of the academic research consortium for high bleeding risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention 16:371–379CrossRef
21.
Zurück zum Zitat Cao D, Mehran R, Dangas G et al (2020) Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. J Am Coll Cardiol 75:2711–2722CrossRef Cao D, Mehran R, Dangas G et al (2020) Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. J Am Coll Cardiol 75:2711–2722CrossRef
22.
Zurück zum Zitat Schupke S, Neumann FJ, Menichelli M et al (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381:1524–1534CrossRef Schupke S, Neumann FJ, Menichelli M et al (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381:1524–1534CrossRef
23.
Zurück zum Zitat Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166CrossRef Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166CrossRef
24.
Zurück zum Zitat Bonaca MP, Braunwald E, Sabatine MS (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 373:1274–1275PubMed Bonaca MP, Braunwald E, Sabatine MS (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 373:1274–1275PubMed
25.
Zurück zum Zitat Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330CrossRef Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330CrossRef
26.
Zurück zum Zitat Khan SU, Singh M, Valavoor S et al (2020) Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation 142:1425–1436CrossRef Khan SU, Singh M, Valavoor S et al (2020) Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation 142:1425–1436CrossRef
27.
Zurück zum Zitat Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423–2434CrossRef Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423–2434CrossRef
28.
Zurück zum Zitat Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524CrossRef Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524CrossRef
29.
Zurück zum Zitat Lopes RD, Heizer G, Aronson R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524CrossRef Lopes RD, Heizer G, Aronson R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524CrossRef
30.
Zurück zum Zitat Vranckx P, Valgimigli M, Eckardt L et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 394:1335–1343CrossRef Vranckx P, Valgimigli M, Eckardt L et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 394:1335–1343CrossRef
31.
Zurück zum Zitat Poess J (2021) Akutes Koronarsyndrom ohne persistierende ST-Strecken-Hebung – was ist neu in den 2020 Leitlinien der ESC. Aktuel Kardiol 10(02):105–111CrossRef Poess J (2021) Akutes Koronarsyndrom ohne persistierende ST-Strecken-Hebung – was ist neu in den 2020 Leitlinien der ESC. Aktuel Kardiol 10(02):105–111CrossRef
32.
Zurück zum Zitat Adlam D, Alfonso F, Maas A et al (2018) European society of cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. Eur Heart J 39:3353–3368CrossRef Adlam D, Alfonso F, Maas A et al (2018) European society of cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. Eur Heart J 39:3353–3368CrossRef
33.
Zurück zum Zitat Tamis-Holland JE, Jneid H, Reynolds HR et al (2019) Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American heart association. Circulation 139:e891–e908CrossRef Tamis-Holland JE, Jneid H, Reynolds HR et al (2019) Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American heart association. Circulation 139:e891–e908CrossRef
35.
Zurück zum Zitat Safdar B, Spatz ES, Dreyer RP et al (2018) Presentation, clinical profile, and prognosis of young patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): results from the VIRGO study. J Am Heart Assoc 7(13):e9174CrossRef Safdar B, Spatz ES, Dreyer RP et al (2018) Presentation, clinical profile, and prognosis of young patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): results from the VIRGO study. J Am Heart Assoc 7(13):e9174CrossRef
36.
Zurück zum Zitat Poess J (2021) Stellenwert von MINOCA beim N‑STEMI. Aktuel Kardiol 10(02):138–142CrossRef Poess J (2021) Stellenwert von MINOCA beim N‑STEMI. Aktuel Kardiol 10(02):138–142CrossRef
37.
Zurück zum Zitat Agewall S, Beltrame JF, Reynolds HR et al (2017) ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J 38:143–153PubMed Agewall S, Beltrame JF, Reynolds HR et al (2017) ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J 38:143–153PubMed
38.
Zurück zum Zitat Mach F, Baigent C, Catapano AL et al (2019) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J 41:111–188CrossRef Mach F, Baigent C, Catapano AL et al (2019) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J 41:111–188CrossRef
Metadaten
Titel
Management des akuten Koronarsyndroms ohne ST-Strecken-Hebung
verfasst von
PD Dr. Maria Rubini Gimenez
Prof. Dr. Holger Thiele
PD Dr. med. Janine Pöss
Publikationsdatum
14.06.2022
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 4/2022
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-022-05120-y

Weitere Artikel der Ausgabe 4/2022

Herz 4/2022 Zur Ausgabe